Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33194
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCollins, Michael G-
dc.contributor.authorFahim, Magid A-
dc.contributor.authorPascoe, Elaine M-
dc.contributor.authorHawley, Carmel M-
dc.contributor.authorJohnson, David W-
dc.contributor.authorVarghese, Julie-
dc.contributor.authorHickey, Laura E-
dc.contributor.authorClayton, Philip A-
dc.contributor.authorDansie, Kathryn B-
dc.contributor.authorMcConnochie, Rachael C-
dc.contributor.authorVergara, Liza A-
dc.contributor.authorKiriwandeniya, Charani-
dc.contributor.authorReidlinger, Donna-
dc.contributor.authorMount, Peter F-
dc.contributor.authorWeinberg, Laurence-
dc.contributor.authorMcArthur, Colin J-
dc.contributor.authorCoates, P Toby-
dc.contributor.authorEndre, Zoltan H-
dc.contributor.authorGoodman, David-
dc.contributor.authorHoward, Kirsten-
dc.contributor.authorHowell, Martin-
dc.contributor.authorJamboti, Jagadish S-
dc.contributor.authorKanellis, John-
dc.contributor.authorLaurence, Jerome M-
dc.contributor.authorLim, Wai H-
dc.contributor.authorMcTaggart, Steven J-
dc.contributor.authorO'Connell, Philip J-
dc.contributor.authorPilmore, Helen L-
dc.contributor.authorWong, Germaine-
dc.contributor.authorChadban, Steven J-
dc.date2023-
dc.date.accessioned2023-06-30T06:19:37Z-
dc.date.available2023-06-30T06:19:37Z-
dc.date.issued2023-07-08-
dc.identifier.citationLancet (London, England) 2023-07-08; 402(10396)en_US
dc.identifier.issn1474-547X-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33194-
dc.description.abstractDelayed graft function (DGF) is a major adverse complication of deceased donor kidney transplantation. Intravenous fluids are routinely given to patients receiving a transplant to maintain intravascular volume and optimise graft function. Saline (0·9% sodium chloride) is widely used but might increase the risk of DGF due to its high chloride content. We aimed to test our hypothesis that using a balanced low-chloride crystalloid solution (Plasma-Lyte 148) instead of saline would reduce the incidence of DGF. BEST-Fluids was a pragmatic, registry-embedded, multicentre, double-blind, randomised, controlled trial at 16 hospitals in Australia and New Zealand. Adults and children of any age receiving a deceased donor kidney transplant were eligible; those receiving a multi-organ transplant or weighing less than 20 kg were excluded. Participants were randomly assigned (1:1) using an adaptive minimisation algorithm to intravenous balanced crystalloid solution (Plasma-Lyte 148) or saline during surgery and up until 48 h after transplantation. Trial fluids were supplied in identical bags and clinicians determined the fluid volume, rate, and time of discontinuation. The primary outcome was DGF, defined as receiving dialysis within 7 days after transplantation. All participants who consented and received a transplant were included in the intention-to-treat analysis of the primary outcome. Safety was analysed in all randomly assigned eligible participants who commenced surgery and received trial fluids, whether or not they received a transplant. This study is registered with Australian New Zealand Clinical Trials Registry, (ACTRN12617000358347), and ClinicalTrials.gov (NCT03829488). Between Jan 26, 2018, and Aug 10, 2020, 808 participants were randomly assigned to balanced crystalloid (n=404) or saline (n=404) and received a transplant (512 [63%] were male and 296 [37%] were female). One participant in the saline group withdrew before 7 days and was excluded, leaving 404 participants in the balanced crystalloid group and 403 in the saline group that were included in the primary analysis. DGF occurred in 121 (30%) of 404 participants in the balanced crystalloid group versus 160 (40%) of 403 in the saline group (adjusted relative risk 0·74 [95% CI 0·66 to 0·84; p<0·0001]; adjusted risk difference 10·1% [95% CI 3·5 to 16·6]). In the safety analysis, numbers of investigator-reported serious adverse events were similar in both groups, being reported in three (<1%) of 406 participants in the balanced crystalloid group versus five (1%) of 409 participants in the saline group (adjusted risk difference -0·5%, 95% CI -1·8 to 0·9; p=0·48). Among patients receiving a deceased donor kidney transplant, intravenous fluid therapy with balanced crystalloid solution reduced the incidence of DGF compared with saline. Balanced crystalloid solution should be the standard-of-care intravenous fluid used in deceased donor kidney transplantation. Medical Research Future Fund and National Health and Medical Research Council (Australia), Health Research Council (New Zealand), Royal Australasian College of Physicians, and Baxter.en_US
dc.language.isoeng-
dc.titleBalanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleLancet (London, England)en_US
dc.identifier.affiliationCentral Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia; Department of Renal Medicine, Auckland City Hospital, Auckland, New Zealand; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia; Australasian Kidney Trials Network, Centre for Health Services Research, University of Queensland, Brisbane, QLD, Australia.en_US
dc.identifier.affiliationDepartment of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, QLD, Australia.en_US
dc.identifier.affiliationCentral Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia; Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.en_US
dc.identifier.affiliationFaculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia; Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.en_US
dc.identifier.affiliationDepartment of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand.en_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationNephrologyen_US
dc.identifier.affiliationDepartment of Anaesthesia, Austin Health, Melbourne, VIC, Australia; Department of Critical Care, University of Melbourne, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationDepartment of Critical Care Medicine, Auckland City Hospital, Auckland, New Zealand.en_US
dc.identifier.affiliationCentral Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.en_US
dc.identifier.affiliationDepartment of Nephrology, Prince of Wales Hospital, Sydney, NSW, Australia; Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.en_US
dc.identifier.affiliationDepartment of Nephrology, St Vincent's Hospital, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationSchool of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Menzies Centre for Health Policy and Economics, University of Sydney, Sydney, NSW, Australia.en_US
dc.identifier.affiliationDepartment of Nephrology and Renal Transplantation, Fiona Stanley Hospital, Murdoch, WA, Australia; School of Medicine, University of Western Australia, Perth, WA, Australia.en_US
dc.identifier.affiliationDepartment of Nephrology, Monash Health, Melbourne, VIC, Australia; Centre for Inflammatory Diseases, Department of Medicine, Monash University, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationInstitute of Academic Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia.en_US
dc.identifier.affiliationSchool of Medicine, University of Western Australia, Perth, WA, Australia; Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia.en_US
dc.identifier.affiliationChild and Adolescent Renal Service, Queensland Children's Hospital, Brisbane, QLD, Australia.en_US
dc.identifier.affiliationCentre for Transplant and Renal Research, Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia; Department of Renal and Transplantation Medicine, Westmead Hospital, Sydney, NSW, Australia.en_US
dc.identifier.affiliationDepartment of Renal Medicine, Auckland City Hospital, Auckland, New Zealand; Department of Medicine, University of Auckland, Auckland, New Zealand.en_US
dc.identifier.affiliationSchool of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Centre for Transplant and Renal Research, Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia; Department of Renal and Transplantation Medicine, Westmead Hospital, Sydney, NSW, Australia.en_US
dc.identifier.affiliationKidney Node, Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia; Department of Renal Medicine, Kidney Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia.en_US
dc.identifier.doi10.1016/S0140-6736(23)00642-6en_US
dc.type.contentTexten_US
dc.identifier.pubmedid37343576-
local.name.researcherMount, Peter F
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptNephrology-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptAnaesthesia-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

40
checked on Feb 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.